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Pharmacokinetics of insulin-like growth factor.! in advanced chronic
renal failure. Information regarding the impact of chronic renal failure
(CRF) on IGF-1 serum clearance is limited. Thus we evaluated the
pharmacokinetics of insulin-like growth factor-I (IGF-l) in six normal
adults and six adults with advanced CRF (serum creatinine 7 0.8 mgldl).
All subjects were given 80 pg/kg recombinant human IGF-1 s.c. and blood
was sampled over 48 hours. Baseline total serum JGF-1 levels were similar
in both groups, but peak levels were elevated significantly in CRF; this was
apparently related to the reduced distribution volume in CRF subjects.
CRF did not affect the metabolic clearance rate (MCR) of total serum
IGF-1. Immunoreactive IGF binding protein-3 (IGFBP-3) levels were
greater in CRF. Western immunoblots revealed that the apparent increase
in IGFBP-3 was largely due to an increase in immunoreactive fragments.
IGFBP-3 protease activity was not increased. Thus IGFBP fragment
accumulation likely reflects reduced fragment clearance. Western ligand
blots revealed elevated 30 and 34 kDa IGFBP levels and IGFBP products
in CRF serum. Serum acid labile subunit levels were unchanged in CRF.
Peak free IGF-I levels and the MCR of free lGF-I did not differ between
groups. In both groups the MCR of free IGF- I exceeded the MCR of total
JGF-1 by approximately 30-fold. These data suggest that in CRF patients
receiving s.c. IGF-1: (a) total serum IGF-1 levels are increased as a result
of elevated circulating IGFBPs that may restrict the distribution of IGF-1
beyond plasma; (b) serum free IGF-1 levels are not altered; and (c) the
IGF-1 MCR is unchanged in CRF. Thus, in advanced CRF, apart from a
reduction in the total IGF-l volume of distribution the pharmacokinetics
of IGF-1 are largely unaltered.
Insulin-like growth factor-I is a 7.6 kD member of the insulin-
related peptide family that is produced in tissues throughout the
body, especially liver [1]. In the circulation, IGF-1 resides largely
bound to circulating high affinity IGF binding proteins (IGFBP)
but less than 1% is present as the free uncomplexed hormone [2].
Altogether six IGF binding proteins have been identified. In the
circulation IGFBP-3 is by far the most abundant with lesser
amounts of IGFBP-1, 2, 4 and -6 present. Usually —90% of the
plasma IGF-1 circulates complexed to both IGFBP-3 (—- 40 to 50
kD depending on glycosylation) and an acid labile subunit (ALS)
(—85 kD) forming a 1150 kD moiety. A small amount is bound to
IGFBP-I, -2, -4 and -6 forming smaller complexes. Because of the
size of the IGF-IGFBP complex, it is thought that IGFBPs limit
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transcapillary passage of IGF-1 resulting in prolongation of the
serum clearance of IGF-1. This is especially evident with IGF-1 in
the 150 kD moiety. Release of IGF-1 from IGFBP complexes is
achieved, in part, by circulating and tissue proteases which lower
the affinity of the IGFBP to IGF-1 [3].
Adding further to the complexity of IGF-1 physiology are the
wide fluctuations of plasma IGFBP concentrations that occur in
response to physiologic and pathologic stimuli. For example,
during fasting or pregnancy, plasma intact IGFBP-3 levels fall [3].
In diabetes there is a fall in IGFBP-3 levels while IGFBP-1 levels
rise [4], and in chronic renal failure the concentration of several
IGFBPs increase [5, 6]. It has been suggested that the increase in
plasma IGFBPs in renal failure reduces IGF-1 bioavailability,
thereby contributing to the uremia-induced resistance to IGF-1
[7].
In general the kidney is a major site of protein hormone
removal, and in renal failure the serum clearance of peptide
hormones, including that of insulin and proinsulin, is reduced [8].
Given the profound changes in the serum IGFBP profile that
occur in chronic renal failure (CRF) and the loss of the kidney as
a source of IGF-1 clearance, we postulated that the pharmacoki-
neties of IGF-l will be altered in renal failure. If true this may
have important clinical implications since IGF-l is under evalua-
tion for the treatment of some of the consequences of renal failure
[9, 10]. We therefore sought to determine the effect of advanced
renal failure on the pharmacokinetics of subcutaneously admin-
istered IGF-1.
Methods
We studied six healthy adult males and six adult males with
advanced chronic renal failure. All subjects gave their consent
under a protocol approved by the Stanford University Medical
Center Human Subjects Review Committee. The key character-
istics of these volunteers are listed in Table 1. The healthy subjects
had no prior history or evidence of renal disease. The entry
criteria for the CRF subjects included a serum creatinine above
2.5 mg/dl, freedom from illness for at least three months and no
requirement for renal dialysis. Exclusion criteria included serious
medical conditions such as malignancy, chronic cardiac, liver or
pulmonary disease, collagen vascular disease, insulin requiring
diabetes, malnutrition (relative body wt < 80% or > 140% of
IBW, serum albumin < 3 g/dl). The cause of renal disease was
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Table 1. Subject characteristics
Normals Patients
(N=6) (N 6)
Ageyears 43±13 45±3
Weight kg 84 7 79 3
BUNmg/dl 13±1 67±9°
Serum creatinine mg/dl 1.1 0.4 7.0 0.3"
Creatinine clearance mI/mm/i. 73 m2 87 8.8 18 2.2°
Serum albumin mg/dl
______
4.5 0.1 4.6 0.2
Data are mean SEM.
"P < 0.01
glomerulonephritis in four subjects and polycystic kidney disease
in two.
The subjects were admitted to the Aging Study Unit at the V.A.
Palo Alto Health Care System the day before the pharmacokinetic
study. They were placed on a 0.8 to 1.0 g protein/kg and 3 to 4 g
salt intake per day and a 24 hours urine collection was obtained.
The next morning, an intravenous catheter was placed in an arm
vein and baseline blood samples were taken 30 minutes and five
minutes prior to injection of IGF-1. Then 80 g/kg recombinant
human IGF-1 (Genentech Inc., South San Francisco, CA, USA)
was administered rapidly s.c. in the contralateral triceps area, and
the patient ate breakfast. Blood was obtained 15, 30, 45, 60 and 90
minutes and 2, 3,4,5,6, 8, 10, 12, 16, 24, 36,40 and 48 hours after
the injection for measurement of glucose, total and free IGF-1
and IGF binding protein levels. The subjects were allowed free
access to snacks and calorie containing fluids and were given
regular meals at 12 noon, 6 p.m. and 7 a.m. Blood pressure was
monitored every 30 minutes for the first one hour after IGF-1
injection then hourly for the next three hours, and then every six
to eight hours.
Radiolabeling of peptides
Serum IGF-1, IGF-2 and non-glycosylated IGFBP-3 were
iodinated by the chloramine-T method [11]; covalent tracer of
[1251J1GF-2 and IGFBP-3 was prepared and purified as described
previously [121. Recombinant IGF-1 was obtained from Bachem,
Inc. (Torrance, CA, USA). Recombinant IGF-2 was provided by
Eli Lilly Co. (Indianapolis, IN, USA). Recombinant glycosylated
IGFBP-3 was purchased from Upstate Biotechnology Inc. (Lake
Placid, NY, USA). Non-glycosylated IGFBP-3 was a gift from
Celtrix (Santa Clara, CA, USA).
Radioimmunoassay (RIA)
IGF-1 was measured by RIA after separation from IGFBPs by
G-50 chromatography in acid, as previously described [13]. Anti-
IGF-1 antiserum (UBK487) was provided by Drs. L.E. Under-
wood and J.J. Van Wyk (Chapel Hill, NC, USA) through the
National Hormone and Pituitary Program. Serum IGFBP-3 levels
were measured directly [14] using antiserum against IGFBP-3
developed by Dr. R.G. Rosenfeld [15]. Covalent ['251]IGF-2:
IGFBP-3 was employed as the tracer for this assay. Assays for free
IGF-1 were carried out with kits provided by Diagnostics Systems
Laboratories, Inc. (DSL, Webster, TX, USA). The procedure
employs a two-site immunoradiometric assay principle with a
minimum detection limit of 0.05 ng/ml [16]. The interassay and
intrassay coefficient of variation averages 3.6 and 5.1%, respec-
tively. All samples were analyzed in the same assay.
Western ligand blotting
Three microliters of each serum sample were separated by 12%
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) under non-reducing conditions. Samples were transferred
onto nitrocellulose and probed for IGFBPs with ['251]IGF-l and
-2 as previously described [5, 17].
Western immunoblots
Serum samples were separated by 12% SDS-PAGE under
non-reducing conditions and electroblotted onto nitrocellulose
[181. Following blocking for four hours at room temperature with
0.1 M Tris-HC1, 0.15 M NaCl, and 0.1% Tween 20, pH 7.4 (TTBS)
with 2% BSA (Sigma Chemical Co., St. Louis, MO, USA), the
blot was incubated overnight with anti-IGFBP-3 antibody at
1:1000, or anti-acid labile subunit (ALS) antiserum (DSL) at
1:2000 in TTBS at 4°C. After three 10 minutes washes at room
temperature with TIBS, the blot was incubated with horseradish
peroxidase linked goat anti-rabbit antibody at 1:10,000 (Amer-
sham, Arlington Heights, IL, USA) for one hour at room tem-
perature. After three washes in TTBS, the blot was exposed for
one minute to enhanced chemiluminescence (ECL) reagents
(Amersham), drained, wrapped in Saran°° wrap, and the antibody-
labeled bands were examined by exposure to ECL hyperfilm
(Amersharn) for 10 to 30 seconds.
IGFBP-3 protease assay
IGFBP-3 specific protease in serum was measured as described
by Giudice et at [19]. Two microliters of serum were incubated
with 30,000 cpm ['251]IGFBP-3 (non-glycosylated) for four hours
at 37°C. Term pregnancy serum was used as a positive control.
After separation by 12% SDS-PAGE, intact and fragmented
IGFBP-3 tracer were detected by autoradiography.
Pharmacokinetic analysis
Free and total serum IGF-1 concentrations (above baseline)
over time for each subject were analyzed by compartmental
modeling, and pharmacokinetic parameters describing absorp-
tion, distribution, and clearance were calculated by standard
methods (PCNONLIN, SCI Software, Lexington, KY, USA). The
maximum serum free or total IGF-1 concentrations and
the times of the maximum concentrations (tmax) were the ob-
served values. The absorption half-life was calculated from the
apparent absorption rate constant:
Absorption half-life = 0.693/absorption rate constant
and the half-life for the disappearance of IGF-1 from the serum
was estimated from the rate decline in serum IGF-1 concentra-
tions (k):
half-life = 0.693/k
Because the subcutaneous availability of IGF-1 was not deter-
mined in this study, distribution volume and serum clearance were
not corrected for bioavailability (F). The distribution volume
(Vd/F) was a parameter of the compartmental fit. The serum
IGF-1 metabolic clearance rate (MCR) was calculated from the
area under the serum IGF-1 concentration versus time curve
extrapolated to infinity (AUC):
MCR = Dose/AUC
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Fig. 1. Serum immunoreactive IGFBP-3 levels immediately he/öre and after
the s.c. injection of !GF-l, 80 j.tglkg, in normal 0 and CItE • subjects.
The assumed endogenous production rate of IGF-1 was estimated
from the serum clearance and baseline total IGF-l concentration
[20. This estimation assumes that the baseline serum IGF-1
concentration represents the concentration of IGF-1 in serum
over the period of study, that the MCR and production rate
remain constant after the administration of IGF-1 and finally that
there is no synthesis or degradation of IGF-1 in relatively large
slow exchange compartments.
Statistical analysis
Values are expressed as the mean SCM. Data were analyzed
for statistical significance by Student's l-tcst.
Results
Serum IGE binding protein profile
In CRF subjects the serum immunoreactive IGFBP-3 levels
were significantly elevated (P < 0.05) throughout the study period
when compared to the normal controls (Fig. 1). There was no
significant change in thcse levels following the s.c. administration
of a single dose of IGF-1. Western ligand analysis, which is
dependent on the ability of the IGFBP to bind radioligand, is
depicted in Figure 2A. Most conspicuous was a 38 to 42 kDa
doublet, the size of IGFBP-3, which was similar in the CRF and
control serum. A 34 kDa band consistent with IGFBP-2 and a
band at 30 kDa, which could represent IGFBP-1, 5 and perhaps 6,
was more prominent in the CRF serum. A 24 kDa band consistent
with IGFBP-4 was similar in the two groups. A diffuse signal seen
between the 26 to 30 kDa region of the gel probably represents
fragmented or deglycosylated IGFBPs. The IGFBP profile did not
appear to change following IGF-1 administration.
Western immunoblots were then performed to characterize
IGFBP-3 in greater detail (Fig. 2B). The immunoblots revealed
that the 38 to 42 kDa doublet is in fact immunoreaetive IGFBP-3
and the levels appeared to be similar in the two groups. The
antibody also detected a 29 kDa protein which was more conspic-
uous in the CRF serum. This presumably represents an immuno-
reactive IGFBP-3 cleavage product. Interestingly, IGFBP-3 pro-
tease activity was not increased in the CRF subjects compared to
controls. This suggests that the elevated levels of the 29 kDa
IGFBP-3 fragment reflects reduced elimination rather than in-
creased production. A representative autoradiogram from a pro-
tease assay is depicted in Figure 3. Western immunoblots per-
formed to measure ALS revealed that the levels in CRF serum did
not differ significantly from normal control levels (data not
shown). IGF-l administration did not affect serum ALS levels.
Serum total IGF- I kinetics
The calculated serum total IGF'-l pharmaeokinetic parameters
are summarized in Table 2 and Figure 4. The change in serum
total IGF-l levels after administration of IGF-1 s.c. is shown in
Figure 5. Baseline serum total IGF-1 levels did not differ between
CRF and normal subjects (140 8 vs. 130 16 ng/ml). However,
maximum serum total IGF-1 levels following s.c. IGF-1 injection
were significantly higher in the CRF subjects (720 74 vs. 530
26 ng/ml in controls; P C 0.05). The time taken to achieve these
peak levels, while on average faster in CRF, did not differ
significantly between groups. Of note, the IGF-1 volume of
distribution was significantly lower in the CRF group (98 9 vs.
150 20 ml/kg; P C 0.05). Since the MCR did not differ
significantly between the groups, the increase in maximum serum
IGF-1 levels appears to be due to the reduced volume of
distribution. Serum total IGF-1 half-life did not differ significantly
between the groups. The estimated assumed endogenous IGF-1
production rate was similar in the CRF and control subjects,
averaging 29 4 and 38 11 gig/kg/day, respectively.
Serum free IGE-] kinetics
The serum free IGF-1 time course after s.c. administration of
IGF-1 is shown in Figure 6 and the results of the pharmaeokinetie
analysis is summarized in Figure 4. While the free serum IGF-1
levels were on average higher during the 4 to 16 hours period after
the IUF-1 was given, there were no significant differences between
the control and CRF subjects in any of the measured serum free
IGF-1 parameters. There were, however, major differences be-
tween the pharmacokinetics of free IGF-1 and total IGF-1 (Fig.
4). Maximum serum free IGF-1 levels in the two groups (22 2
and 23 I ng/ml) accounted for less than one tenth of the
maximum total serum IGF-i levels. The MCR of free lOP-i in
normal and CRF subjects (360 73 and 290 65 ml/min/kg)
exceeded that of the total IOF-1 MCR (11 0.2 and 10 0.2
mI/mm/kg) measured in the same subjects by - 30-fold. The
volume of distribution of free lOP-i, 3.9 0.82 and 3.0 0.24
liter/kg in normal and CRF subjects, respectively, exceeded the
volume of distribution of total lOP-i by a similar order of
magnitude.
Discussion
In this study we observed that following the administration of a
single s.c. dose of recombinant human 1GF-1, the serum lOP-i
rose to higher maximum levels in subjects with advanced CRF
than in normals. Unexpectedly the serum total TOP-i MCR was
unchanged, despite a major loss of renal function. Serum free
LOP-i rose similarly in the two study groups, and again there were
no significant group differences between the free LOP-i MCR or
volume of distribution. As anticipated, the volume of distribution
and MCR of serum free LOP-i were considerably greater than the
corresponding total LOP-i parameters. It should be noted that the
free LOP-i assayed likely reflects true free IOF-1 and IOF-1 that
rapidly dissociates from TOFBPs (presumably the low molecular
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Fig. 2. (A) Western ligand blot of IGFBPs in serum of a normal and CRF subject 0.5 hours before and 4 and 24 hours after the administration of IGF-1
s.c. (B) Western immunoblot with antibody against TGFBP-3 of serum of a normal and CRF subject.
Data are mean SEM.
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Fig. 3. JGFBP-3protease assay. Pregnancy serum and serum taken from a
normal and CRF subject 0.5 hours before and two hours after s.c. IGF-1
administration were incubated with recombinant 1251-IGFBP-3 for four
hours. Proteolysis of 251-IGFBP-3 by pregnancy serum is evident while
there is minimal proteolysis in normal and CRF serum.
weight moieties) during the assay [16]. In normal subjects the
estimated assumed IGF-1 production rate averaged 38 iLgIkg/day
and was essentially the same as that reported by Wilton et al [20].
The production rate was not significantly different in CRF (29
p.g/kg/day).
Profound changes in the serum IGFBP profile were apparent in
the CRF subjects that did not change following the single dose of
IGF-1. In these subjects, the serum immunoreactive IGFBP-3
levels were significantly elevated. As judged by Western immuno-
blot, this material consisted of intact IGFBP-3 and a 29 kDa
fragment. Both moieties were present in normal serum but only
the 29 kDa fragment was elevated in the CRF serum. The serum
level of immunoreactive ALS, a glycoprotein that forms a 150 kDa
complex with circulating IGF-1 and IGFBP-3, was not elevated. In
contrast Western ligand blot analysis revealed an increase in the
30 and 34 kDa IGFBPs, which is consistent with the reported
increase in IGFBP-1 and IGFBP-2 in uremia [5, 6]. In addition,
there was a diffuse signal in the 26 to 30 kDa region that likely
reflects IGFBP fragments and perhaps deglycosylated IGFBPs.
Since IGFBPs sequester circulating IGF-1, limiting its passage
into the tissues, it is likely that the increase in serum IGFBPs in
CRF accounts for the lower total IGF-1 volume of distribution in
these subjects. Another likely consequence of IGF-1 trapping by
elevated serum IGFBP levels is attenuated bioavailability [2, 21]
and this may contribute to the resistance to IGF-1 action seen in
uremia [7, 221. There is, however, preliminary evidence suggesting
that skeletal muscle IGF-1 resistance may also be due to a
post-receptor signaling defect [23].
Since the levels of free (bioavailable) IGF-1 were similar in
1 2 3 4 5 6
I II II IIkD
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Table 2. Pharmacokinetic parameters for serum total IGF-1
Normal
(N=6)
CRF
(N=6)
Baseline serum total IGF-1 ng/ml 130 16 140 8
Maximum plasma total IGF-1 (Cm) ng/ml 530 26 720 74
Time to max serum total IGF-1 (tmax) hr 5.7 1.1 4.5 0.78
Distribution volume (V/F) liter/kg 0.15 0.02 0.098 0.Ola
Serum clearance (CL/F) mI/hr/kg 11 2.0 9.6 1.9
Apparent absorption half-life hr 2 0.5 2.1 0.3
Initial half-life hr 7 2.0 5.3 1.4
AUC above baseline (ng/ml) hr 9100 2122 10000 1592
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control and CRF subjects after the acute administration of IGF-i
and as the IGF-1 MCR did not differ between the two groups, it
would appcar from this pharmacokinetic study that the dose of
IGF-1 in CRF, at least in the short term, does not require
modification, However, as resistancc to the metabolic action of
IGF-1 has been noted in patients with end-stage renal disease, the
dose of IGF-1 may need to be adjusted so as to achieve the
desired biologic effect, Furthermore, as discussed below, chronic
administration of IGF-1 may result in changes in IGF-1 pharma-
cokinetics necessitating modification of the IGF-i dosage [10].
In this short term study, the IGFBP levels did not change after
the administration of a single dose of IGF-1. Repeated chronic
administration of IGF-1, especially in large doses, is associated
with a fall in IGFBP-3 levels [24]. This is mediated indirectly
through an IGF-1 induced fall in growth hormone [25]. Studying
patients with advanced CRF, Miller et a! [10] observed a fall in
serum IGFBP-3 levels after prolonged use of IGF-1. This change
L
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Fig. 5. Serum total IGF-1 levels befbre and after the administration of 80
p.g/kg IGF-1 s.c. to six normal (0) and six CRF (•) subjects.
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Fig. 6. Serum free IGF-1 levels over time in the same subjects receiving
IGF-I as in Figure 5. Note the different scales for free and total IGF-1
levels. Symbols are: (S) CRF patients; (0) normal.
in 1GFBP-3 levels may affect IGF-1 pharmaeokineties and in-
crease IGF-1 bioavailability. Higher free IGF-1 levels following
IGF-1 administration could conceivably lead to an increase in
untoward side effects or possibly to increasing resistance to IGF-1
action due to receptor down-regulation. These possibilities must
he considered when planning long term IGF-1 administration [10,
25].
Despite resistance to IGF-1 action in uremia, this hormone may
have an important role in the treatment of patients with CRF.
First, IGF-1 has growth promoting and anabolic properties, and
its administration to rats with CRF results in increased body
weight and growth [26]. In humans with end-stage renal disease on
dialysis, IGF-1 treatment lowers plasma amino acid and glucose
levels [9]. These anaholic properties suggest that IGF-1 may be of
value in treating CRF patients with malnutrition and muscle
wasting. Studies at this center and elsewhere are also underway
exploring the renal function promoting properties of IGF-1.
Miller et at [10] have provided preliminary evidence showing that
short term administration of IGF-1 can improve renal function in
patients with advanced CRF.
Fouque, Peng and Kopple [27] recently reported the findings of
their study of serum total IGF-1 pharmacokinetics in patients with
end-stage renal disease on maintenance hemodialysis or perito-
neal dialysis. As in our study with predialysis patients, they found
that the total serum IGF-1 MCR did not differ significantly from
that measured in normal controls. The volume of serum total
IGF-1 distribution was reduced, and the Cmax was increased.
While they did not measure IGFBP levels, they postulated that
the higher Cmax was likely due to an increase in serum IGFBPs.
Our finding that CRF subjects have elevated serum 1GFBP levels
and a high total IGF-1 Cmax substantiates this hypothesis. In this
same study they noted that the serum total IGF-1 half-life (but not
the MCR) was accelerated when their subjects received IGF-1 in
a dose of 100 jig/kg, but not when they were given a dose of 50
jig/kg. We saw no difference in serum total IGF-l half-life in CRF
patients who received 80 jig/kg per day. Fouquc et al [27]
suggested that the shorter total IGF-1 half-life might reflect lOF-1
binding to IGFBPs that are cleared more readily from the
circulation. If this were true, then the MCR would have been
faster, However, in peritoncal dialysis patients the MCR was
essentially the same as in normal controls; in hemodialysis pa-
tients the MCR, while on average higher, did not differ signifi-
cantly from controls. Accordingly, we suggest that the accelerated
half-life reflects constant clearance from a smaller volume of
distribution. As in this study of pre-end-stage renal failure pa-
tients they found that the estimated 1GF-1 production rate was
unaltered in patients requiring dialysis.
It is well established that the kidney is a major site of clearance
of small protein hormones including insulin and proinsulin [8].
On the other hand, little is known about the renal or the extra-
renal clearance of IGF-1. In part this is due to the difficulty in
measuring IGF-1 clearance, since IGF-1 is tightly complexed to
circulating IGFBPs and escapes very slowly out of the circulation.
Indeed, IGF-1 half-life is measured in hours whereas the half-life
for insulin is measured in minutes. Distribution studies in animals
show that after an i.v. injection, IGF-1 reaches a higher concen-
tration in the kidney than in any other organ [28]. Nevertheless,
the true role of the kidney in IGF-1 clearance and metabolism is
still unclear. The present study and that of Fouque [271 showing
that advanced chronic renal failure does not affect IGF-1 meta-
bolic clearance suggests that the kidney may not be an important
organ in IGF-1 disposal. On the other hand, it is conceivable that
other uremia-induced changes, such as increased skeletal muscle
receptor number [23], may increase extrarenal removal and
compensate for any reduction in renal clearance.
it has been stated that release of IGF-1 from IGFBPs is
achieved in part through proteolytic cleavage of the IGFBP, which
then results in reduced affinity for IGF-1 [3]. In some conditions,
such as pregnancy, trauma, and type II diabetes, serum protease
activity is increased [3, 4, 291 and in some patients with chronic
renal disease urinary IGFBP-3 protease activity is also increased
[30]. Our observation of increased levels of immunoreactive
IGFBP-3 fragments in CRF serum raised the possibility of
increased IGFBP-3 protease activity. However, measured pro-
tease activity was not increased. Accordingly, we conclude that the
increase in IGFBP-3 fragment production reflects reduced renal
clearance.
In summary, we have shown that unlike the closely related
protein hormone insulin, the pharmacokinetics of iGF-1 is largely
unaltered in advanced chronic renal failure. We attribute this
difference from other protein hormones to the presence of serum
IGF binding proteins which restrict the passage of IGF-1 out of
the circulation and thus profoundly affect IGF-1 clearance. In
CRF, elevated serum IGFBP levels reduce the total IGF-1 volume
of distribution and this results in an increase in the maximum total
serum IGF-1 levels following acute administration of the hor-
mone. In contrast, serum free IGF-i levels rise to levels compa-
rable to that seen in normal subjects.
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